No abstract

No abstract

Covalent triazine frameworks (CTFs) with high adsorption potential and photocatalytic ability features are expected to be designed as a new class of adsorbents that can regenerate themselves just by harnessing sunlight. To simultaneously improve both the adsorption and photocatalytic regeneration performance, a defect-abundant CTF-m was designed and tuned effectively by varying the lengths of benzene ring chains incorporated into the CTF backbone. It has been demonstrated that two kinds of defects in terms of broken benzene rings and pyrrole nitrogen were newly generated, other than the normal benzene rings and triazine units in the CTF-m skeleton. Benefiting from these defects, the adsorption sites with high energy for adsorbing volatile aromatic pollutants were significantly increased, which are reflected by higher saturated adsorption capacities of CTF-m (3.026 mmol/g for benzene (BEN), 1.490 mmol/g for naphthalene (NAP), and 0.863 mmol/g for phenol (PHE)) compared with those of CTF-1 and CTF-2. Furthermore, these defects narrowed the band structure and facilitated the separation of photogenerated charge carries, thus promoting photocatalytic regeneration. The percentage of CTF-m regenerated was still higher than 90% in the fourth cycle. These experimental results, together with the density functional theory (DFT) studies, soundly corroborated that the defects could optimize the adsorption and regeneration property of CTF-m. The present work highlights the potential of fabrication of defective CTFs as solar-driven self-cleaning adsorbents to remove pollutants from water.

low-dose ipilimumab in advanced NSCLC. Here we evaluate this regimen as first-line treatment in special populations (cohort A1) and a reference population (cohort A; previously reported). Method: Patients had previously untreated advanced NSCLC. Cohort A1 (n¼198) had ECOG PS 2 or ECOG PS 0e1 with 1 of: asymptomatic untreated brain metastases, hepatic or renal impairment, or HIV. Cohort A (n¼391) had ECOG PS 0e1. Patients with known EGFR mutations or ALK translocations sensitive to available targeted therapy were excluded from both cohorts. Nivolumab 240 mg Q2W plus ipilimumab 1 mg/kg Q6W was administered for two years or until disease progression/unacceptable toxicity. Safety and efficacy endpoints were assessed; cohort A1 analyses were exploratory. Result: Cohort A1 patients were grouped as: ECOG PS 2 (n¼139) and all other special populations (AOSP; n¼59). Baseline characteristics were generally balanced between cohorts. Rates of grade 3e4 treatment-related adverse events (TRAEs) were similar between cohorts; within cohort A1, grade 3e4 TRAEs were numerically higher in AOSP versus the ECOG PS 2 subgroup; TRAEs leading to discontinuation were similar across populations (Table). ORR was 25% in cohort A1 (patients with ECOG PS 2, 20%; AOSP, 37%) and 35% in cohort A. PFS was numerically shorter in cohort A1 than cohort A; high TMB (10 mut/Mb) and higher PD-L1 expression (1% or 50%) were associated with numerically longer PFS in both cohorts (Table). Conclusion: First-line flat-dose nivolumab plus weight-based ipilimumab showed a consistent safety profile in special populations with advanced NSCLC, including those with ECOG PS 2. Patients with either high TMB or higher tumor PD-L1 expression appeared to exhibit improved efficacy.